Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is a progressive liver disease with potentially severe complications including cirrhosis and hepatocellular carcinoma. Previously, we have identified circulating lipid signatures associating with liver fat content and non-alcoholic steatohepatitis (NASH). Here, we develop a metabolomic map across the NAFLD spectrum, defining interconnected metabolic signatures of steatosis (non-alcoholic fatty liver, NASH, and fibrosis). Methods: We performed mass spectrometry analysis of molecular lipids and polar metabolites in serum samples from the European NAFLD Registry patients (n = 627), representing the full spectrum of NAFLD. Using various univariate, multivariate, and machine learning statistical approaches, we interrogated metabolites across 3 clinical perspectives: steatosis, NASH, and fibrosis. Results: Following generation of the NAFLD metabolic network, we identify 15 metabolites unique to steatosis, 18 to NASH, and 15 to fibrosis, with 27 common to all. We identified that progression from F2 to F3 fibrosis coincides with a key pathophysiological transition point in disease natural history, with n = 73 metabolites altered. Conclusions: Analysis of circulating metabolites provides important insights into the metabolic changes during NAFLD progression, revealing metabolic signatures across the NAFLD spectrum and features that are specific to NAFL, NASH, and fibrosis. The F2-F3 transition marks a critical metabolic transition point in NAFLD pathogenesis, with the data pointing to the pathophysiological importance of metabolic stress and specifically oxidative stress. Clinical Trials registration: The study is registered at Clinicaltrials.gov (NCT04442334). Lay summary: Non-alcoholic fatty liver disease is characterised by the build-up of fat in the liver, which progresses to liver dysfunction, scarring, and irreversible liver failure, and is markedly increasing in its prevalence worldwide. Here, we measured lipids and other small molecules (metabolites) in the blood with the aim of providing a comprehensive molecular overview of fat build-up, liver fibrosis, and diagnosed severity. We identify a key metabolic 'watershed' in the progression of liver damage, separating severe disease from mild, and show that specific lipid and metabolite profiles can help distinguish and/or define these cases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“The world’s leading cause of chronic liver disease, NAFLDhas been estimated to affect 25%of the adult population and continues to rise with increasing rates of obesity.(2) NAFLD is associated with several comorbidities including components of metabolic syndrome (type 2 diabetes mellitus [T2DM], hypertension, anddyslip…”
BackgroundSelf-citationA lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Taylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.043 · Cited by 1,069
Self-citationFloegel, A., Stefan, N., Yu, Z., Mühlenbruch, K., Drogan, D., Joost, H.-G., Fritsche, A., Häring, H.-U., Hrabě de Angelis, M., Peters, A., et al. (2013) · Diabetes · doi:10.2337/db12-0495 · Cited by 988
Novel biomarkers for pre-diabetes identified by metabolomics
Wang‐Sattler, R., Yu, Z., Herder, C., Messias, A. C., Floegel, A., He, Y., Heim, K., Campillos, M., Holzapfel, C., Thorand, B., et al. (2012) · Molecular Systems Biology · doi:10.1038/msb.2012.43 · Cited by 701
Rhee, E. P., Cheng, S., Larson, M. G., Walford, G. A., Lewis, G. D., McCabe, E., Yang, E., Farrell, L., Fox, C. S., O’Donnell, C. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44442 · Cited by 647 · cited 1×
“The TGs that increase in NASH include those TGs with low carbon number and double bond count, which were previously found to be associated with de novo lipogenesis,(25) insulin resistance,(26) NAFLD,(10) and with increased risk of type 2 diabetes.(27) As compared with other assessments performed at biopsy (including s…”
ResultGovaere, O., Cockell, S., Tiniakos, D., Queen, R., Younes, R., Vacca, M., Alexander, L., Ravaioli, F., Palmer, J., Petta, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba4448 · Cited by 479
Self-citationLuukkonen, P. K., Zhou, Y., Sädevirta, S., Leivonen, M., Arola, J., Orešič, M., Hyötyläinen, T., & Yki-Järvinen, H. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.002 · Cited by 461
Self-citationMetabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Masoodi, M., Gastaldelli, A., Hyötyläinen, T., Arretxe, E., Alonso, C., Gaggini, M., Brosnan, J., Anstee, Q. M., Millet, O., Ortiz, P., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00502-9 · Cited by 451
Self-citationLuukkonen, P. K., Sädevirta, S., Zhou, Y., Kayser, B., Ali, A., Ahonen, L., Lallukka, S., Pelloux, V., Gaggini, M., Jian, C., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0071 · Cited by 428
Self-citation
Research works printed but not linked: 23
- Anstee, 2013, Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis, Nat Rev Gastroenterol Hepatol, 10, 330, 10.1038/nrgastro.2013.41 · DOI · Paper page
- Byrne, 2015, NAFLD: a multisystem disease, J Hepatol, 62, S47, 10.1016/j.jhep.2014.12.012 · DOI · Paper page
- Friedman, 2018, Mechanisms of NAFLD development and therapeutic strategies, Nat Med, 24, 908, 10.1038/s41591-018-0104-9 · DOI · Paper page
- Anstee, 2020, Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort, J Hepatol, 73, 505, 10.1016/j.jhep.2020.04.003 · DOI · Paper page
- Orešič, 2013, Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids, Diabetologia, 56, 2266, 10.1007/s00125-013-2981-2 · DOI · Paper page
- Barr, 2012, Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression, J Proteome Res, 11, 2521, 10.1021/pr201223p · DOI · Paper page
- Vvedenskaya, 2021, Nonalcoholic fatty liver disease stratification by liver lipidomics, J Lipid Res, 62, 100104, 10.1016/j.jlr.2021.100104 · DOI
- Hardy, 2020, The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease, Contemp Clin Trials, 98, 106175, 10.1016/j.cct.2020.106175 · DOI · Paper page
- Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 · DOI · Paper page
- Bedossa, 2012, Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients, Hepatology, 56, 1751, 10.1002/hep.25889 · DOI · Paper page
- Pluskal, 2010, MZmine 2: modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data, Bmc Bioinformatics, 11, 395, 10.1186/1471-2105-11-395 · DOI · Paper page
- Castillo, 2011, Data analysis tool for comprehensive two-dimensional gas chromatography/time-of-flight mass spectrometry, Anal Chem, 83, 3058, 10.1021/ac103308x · DOI · Paper page
- Aron-Wisnewsky, 2020, Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders, Nat Rev Gastroenterol Hepatol, 17, 279, 10.1038/s41575-020-0269-9 · DOI · Paper page
- Westerbacka, 2010, Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease, Gastroenterology, 139, 1961, 10.1053/j.gastro.2010.06.064 · DOI
- Burra, 2021, Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), Liver Int, 41, 1713, 10.1111/liv.14943 · DOI · Paper page
- Gall, 2010, alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population, PLoS One, 5, 10.1371/journal.pone.0010883 · DOI · Paper page
- Ferrannini, 2013, Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance, Diabetes, 62, 1730, 10.2337/db12-0707 · DOI · Paper page
- Dean, 2018, Structural and functional roles of ether lipids, Protein Cell, 9, 196, 10.1007/s13238-017-0423-5 · DOI · Paper page
- Hannich, 2020, Ether lipids, sphingolipids and toxic 1-deoxyceramides as hallmarks for lean and obese type 2 diabetic patients, Acta Physiol (Oxf), 232
- Razquin, 2018, Plasma lipidomic profiling and risk of type 2 diabetes in the PREDIMED trial, Diabetes Care, 41, 2617, 10.2337/dc18-0840 · DOI · Paper page
- Suvitaival, 2018, Lipidome as a predictive tool in progression to type 2 diabetes in Finnish men, Metabolism, 78, 1, 10.1016/j.metabol.2017.08.014 · DOI · Paper page
- Lemaitre, 2018, Circulating sphingolipids, insulin, HOMA-IR, and HOMA-B: the strong heart family study, Diabetes, 67, 1663, 10.2337/db17-1449 · DOI · Paper page
- Burla, 2018, MS-based lipidomics of human blood plasma: a community-initiated position paper to develop accepted guidelines, J Lipid Res, 59, 2001, 10.1194/jlr.S087163 · DOI · Paper page
Cited by
Inter-organ crosstalk during development and progression of type 2 diabetes mellitus
Xourafa, G., Korbmacher, M., & Roden, M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00898-1 · Cited by 274
“Multi-omics or specific lipidomics signatures differ between people with NAFLD at risk of or with T2DM (IMI-DIRECT) 237 or across the full histological NAFLD spectrum 238 .”
BackgroundBhattacharya, M., & Ramachandran, P. (2023) · Nature Immunology · doi:10.1038/s41590-023-01551-9 · Cited by 148
Lipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
“105,106 In MASLD, a signi fi cant increase in TAGs with lower carbon numbers and double bonds, 94,102,105 DAGs, 99,102,107 and PE 94,108 – 111 has been reported.”
InfluentialNASH drug treatment development: challenges and lessons
Tilg, H., Byrne, C. D., & Targher, G. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00159-0 · Cited by 81
Metadata
- Authors
- McGlinchey, A. J., Govaere, O., Geng, D., Ratziu, V., Allison, M., Bousier, J., Petta, S., de Oliviera, C., Bugianesi, E., Schattenberg, J. M., Daly, A. K., Hyötyläinen, T., Anstee, Q. M., & Orešič, M.
- Venue
- JHEP Reports
- Publisher
- Elsevier BV
- Published
- 2022-05
- Volume
- 4
- Issue
- 5
- Pages
- 100477
- ISSN
- 2589-5559 (ISSN-L)
- OpenAlex
- W4220707407
- Cited by
- 105
- References
- 15
- FWCI
- 13.78
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- European Federation of Pharmaceutical Industries and Associations
- European Commission (634413, 777377)
- Innovative Medicines Initiative
- NIHR Newcastle Biomedical Research Centre
- Horizon 2020 Framework Programme
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. https://app.cochat.ai/papers/10.1016/j.jhepr.2022.100477
- The paper
- McGlinchey, A. J., Govaere, O., Geng, D., Ratziu, V., Allison, M., Bousier, J., Petta, S., de Oliviera, C., Bugianesi, E., Schattenberg, J. M., Daly, A. K., Hyötyläinen, T., Anstee, Q. M., & Orešič, M. (2022). Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. JHEP Reports. https://doi.org/10.1016/j.jhepr.2022.100477
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.